ABS-201
ABS-201 is in Phase 1/2 for androgenetic alopecia, developed by Absci.
An AI-designed antibody against the prolactin receptor, which its sponsor projects could be dosed a few times a year, in its first human trial since December 2025.
- Developed by
- Absci
- Current phase
- Phase 1/2
- Mechanism
- Prolactin receptor
- Indications
- Androgenetic alopecia
- Also known as
- ABS201, ABS 201
- Last public activity
- September 2026
- Copy last reviewed
- September 2026
- Record confidence
- High
A combined safety and early-efficacy study.
Blocks the prolactin receptor, a hormone signal implicated in follicle miniaturisation.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
Absci designed ABS-201 computationally to block the prolactin receptor, the target HMI-115 reached first. The company's rationale is that blocking prolactin signalling shifts follicles into their growth phase, a route that does not touch DHT.
Why it matters
The second anti-prolactin-receptor antibody in the register, and the more visible: Absci is listed on Nasdaq and reports on a schedule. HEADLINE, a Phase 1/2a in Australia, dosed its first participants in December 2025. In June 2026 the company reported the single-dose part, in healthy volunteers, as well tolerated, with an estimated half-life of at least 65 days, which it says could support two or three injections over six months pending confirmation in longer follow-up. Interim proof-of-concept data are promised for the second half of 2026 and the full read for early 2027. No hair-growth result exists yet.
Development history
- Phase 1/2
First Phase 1/2 trial on record: NCT07317544 — Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Absci Pty Ltd. · n=227 · December 2025
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- ABS-201 for androgenetic alopecia — Company release
- Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia — ClinicalTrials.gov
- Absci announces positive interim Phase 1 data from the HEADLINE trial of ABS-201, a novel antibody targeting the prolactin receptor — Company release, June 2026
Related programmes
Other programmes in the register with the same mechanism: Prolactin receptor.
Cite this page
Hair Pipeline, "ABS-201 — development record", hairpipeline.com/pipeline/abs-201